What is HC Wainwright’s Estimate for Geron Q1 Earnings?

Geron Corporation (NASDAQ:GERN) – Equities researchers at HC Wainwright issued their Q1 2026 EPS estimates for shares of Geron in a note issued to investors on Wednesday, November 5th. HC Wainwright analyst E. Bodnar forecasts that the biopharmaceutical company will earn ($0.04) per share for the quarter. The consensus estimate for Geron’s current full-year earnings is ($0.25) per share. HC Wainwright also issued estimates for Geron’s Q2 2026 earnings at ($0.03) EPS.

Geron (NASDAQ:GERN) last released its earnings results on Wednesday, November 5th. The biopharmaceutical company reported ($0.03) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.03). Geron had a negative net margin of 53.52% and a negative return on equity of 31.37%. The firm had revenue of $47.23 million during the quarter, compared to analyst estimates of $55.24 million.

GERN has been the topic of several other reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Geron in a research report on Friday, October 31st. Needham & Company LLC lowered their price target on Geron from $5.00 to $4.00 and set a “buy” rating on the stock in a report on Wednesday. Finally, The Goldman Sachs Group began coverage on Geron in a research report on Thursday, July 10th. They issued a “sell” rating and a $1.00 target price for the company. Three research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, Geron presently has a consensus rating of “Hold” and an average price target of $3.64.

Geron Stock Down 2.3%

Shares of GERN traded down $0.03 during trading hours on Friday, hitting $1.06. The company had a trading volume of 2,352,760 shares, compared to its average volume of 11,199,604. The stock has a market capitalization of $673.11 million, a price-to-earnings ratio of -8.12 and a beta of 0.57. The firm has a fifty day moving average price of $1.30 and a 200-day moving average price of $1.36. Geron has a 52-week low of $1.04 and a 52-week high of $4.33. The company has a debt-to-equity ratio of 0.46, a quick ratio of 6.79 and a current ratio of 7.87.

Institutional Trading of Geron

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Profund Advisors LLC grew its stake in shares of Geron by 21.3% during the 3rd quarter. Profund Advisors LLC now owns 213,466 shares of the biopharmaceutical company’s stock valued at $292,000 after acquiring an additional 37,535 shares during the period. Candriam S.C.A. increased its stake in Geron by 71.6% in the 3rd quarter. Candriam S.C.A. now owns 3,253,960 shares of the biopharmaceutical company’s stock worth $4,458,000 after buying an additional 1,358,068 shares in the last quarter. Ballentine Partners LLC raised its holdings in Geron by 14.5% during the third quarter. Ballentine Partners LLC now owns 93,971 shares of the biopharmaceutical company’s stock valued at $129,000 after acquiring an additional 11,887 shares during the period. Y Intercept Hong Kong Ltd bought a new position in shares of Geron in the third quarter worth about $171,000. Finally, SG Americas Securities LLC purchased a new stake in shares of Geron during the third quarter worth about $155,000. Hedge funds and other institutional investors own 73.71% of the company’s stock.

About Geron

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.